Home  |  About  |  Photos  |  Contact  |  Privacy

Drew Watson Ph.D.

Advancing Personalized Medicine



Management Leadership, Biostatistics, Personalized Medicine, Molecular Diagnostics


Drew's management training began in 1978 under the tutelage of the late Dr. W. Edwards Deming - considered to be the "Father of the Japanese Industrial Revolution." Under Dr. Deming's direction, Drew consulted and taught courses in management leadership and statistical quality control (SQC) to executives at such companies as Intel, Hewlett-Packard, NEC, Armstrong World Industries, Applied Materials and Dow Chemical.

Drew subsequently received his M.B.A. with an emphasis on strategic management. As part of Drew's continual learning, he routinely attends conferences in leadership and is under the guidance of an executive coach - Kevin Wolf - founder of Leadersway. Drew has over 25 years experience as a manager at the Director/VP level.


Drew has over 35 years of experience as a statistician. Drew entered California State University East Bay as a music major and a track athelete, but soon learned he had a propensity for statistics and mathematics. During the course of his education, he received a student internship in mathematics and statistics at Lawrence Livermore National Laboratory where he studied under the late Dr. Perry Gluckman - a Stanford University trained statistician and reknown statistical consultant. It was during this time that Drew was introduced to Dr. W. Edwards Deming who was relatively unknown in the US at that time. Dr. Deming encouraged Drew to "pursue his Ph.D. in mathematical statistics and many years of statistical consulting."

Drew subsequently received his M.S. in Computational Statistics from Stanford University studying from such famous mathematicians as Dr. George Dantzig, Dr. Gene Golub, Dr. Brad Efron, and Dr. Jerome Friedman. Drew subsequently developed an interest in statistical problems in biological research and received his Ph.D. in Biostatistics from UCLA. Drew's Ph.D. advisor was Dr. Robert Elashoff and his Ph.D. thesis was on influential observations and robust statistical methods in survival analysis. During his entire education, Drew managed a statistical and managerial consulting firm under the guidance of Dr. Perry Gluckman and Dr. W. Edwards Deming. Active areas of statistical research for Drew include the development of statistical and bioinformatic methods in genomics, biomarker discovery and algorithm development, computational pathology, and statistical data mining techniques for large scale studies.


Drew began his intial interest in molecular diagnostics at Chiron Corporation in the early 1990's. During this time, Chiron had purchased its next door neighbor Cetus Corporation in a stock trade worth $660 million. It was during this time that Karry Mullis, who subsequently won the Nobel Prize in Medicine in 1993, discovered polymerase chain reaction (PCR) - a technology fundamental to molecular diagnostics. In additiona to becoming familiar with PCR, Drew was influential in the commercial development of other molecular assay technologies, including branched DNA (bDNA), applied to such infectious diseases as HIV, HBV and HCV. Drew subsequently joined Incyte Genomics where he was General Manager of Incyte Microarray Systems. Here Drew managed a team of researchers in the development of gene and protein expression technologies. Drew currently manages a team of biostatisticians involved in the development of multiple molecular assay technologies including quantiative PCR (qPCR), next generation sequencing (NGS) and digitial pathology.